Nos publications

2.

[Preparation of highly purified microbules and evidence for a novel molecular arrangement at low temperatures].

Delacourte A, Plancot MT, Boutteau F, Han KK, Hildebrand HF, Biserte G.

Biochimie. 1977;59(5-6):479-86. doi: 10.1016/s0300-9084(77)80053-9.

PMID: 889933 French.

3.

Investigation of tubulin fibers formed during microtubule polymerization cycles.

Delacourte A, Plancot MT, Han KK, Hildebrand H, Biserte G.

FEBS Lett. 1977 May 1;77(1):41-6. doi: 10.1016/0014-5793(77)80189-0.

PMID: 858387 No abstract available.

4.

Purification, immunochemical and biological characterization of malate dehydrogenase of Schistosoma mansoni.

Bout D, Dupas H, Capron M, Gazawi AE, Carlier Y, Delacourte A, Capron A.

Immunochemistry. 1978 Sep;15(9):633-8. doi: 10.1016/0161-5890(78)90036-6.

PMID: 738760 No abstract available.

5.

The relevance of viscous behaviour to stress/displacement relationship in pharmaceutical powders compression.

Colombo P, Conte U, Caramella C, La Manna A, Guyot JC, Delacourte A, Devise B, Traisnel M, Boniface M.

Farmaco Prat. 1978 Dec;33(12):531-42.

PMID: 750237 No abstract available.

6.

The isolation of brain 10 nm filament polypeptides from urea-extracts of brain white matter.

Thorpe R, Delacourte A, Anderton BH.

FEBS Lett. 1979 Jul 1;103(1):148-51. doi: 10.1016/0014-5793(79)81269-7.

PMID: 467642 No abstract available.

7.

The polypeptides of isolated brain 10nm filaments and their association with polymerized tubulin.

Thorpe R, Delacourte A, Ayers M, Bullock C, Anderton BH.

Biochem J. 1979 Aug 1;181(2):275-84. doi: 10.1042/bj1810275.

PMID: 574009 Free PMC article.

8.

Study of the 10-nm-filament fraction isolated during the standard microtubule preparation.

Delacourte A, Filliatreau G, Boutteau F, Biserte G, Schrevel J.

Biochem J. 1980 Nov 1;191(2):543-6. doi: 10.1042/bj1910543.

PMID: 7195199 Free PMC article.

9.

Preparation of neurofilaments from three different sources.

Plancke Y, Delacourte A, Biserte G.

Biochimie. 1981 Apr;63(4):365-7. doi: 10.1016/s0300-9084(81)80122-8.

PMID: 7194692 No abstract available.

10.

[Polypeptide composition of neurofilaments of birds].

Filliatreau G, Di Giamberardino L, Delacourte A, Boutteau F, Biserte G.

Biochimie. 1981 Apr;63(4):369-71. doi: 10.1016/s0300-9084(81)80123-x.

PMID: 7194693 French. No abstract available.

11.

Intermediate filament proteins in mouse brain cells cultured in the presence or absence of fetal calf serum.

Prochiantz A, Delacourte A, Daguet MC, Paulin D.

Exp Cell Res. 1982 Jun;139(2):404-10. doi: 10.1016/0014-4827(82)90267-1.

PMID: 7200906 No abstract available.

12.

Characterization of mammalian neurofilament subunits by circular dichroism.

Delacourte A, Dousti M, Loucheux-Lefebvre MH.

Biochim Biophys Acta. 1982 Dec 6;709(1):99-104. doi: 10.1016/0167-4838(82)90426-5.

PMID: 6891266

13.

Accessibility and cross-linking of native neurofilaments to chemical reagents.

Francois C, Delacourte A, Han KK, Mazzuca M.

Int J Biochem. 1984;16(5):461-7. doi: 10.1016/0020-711x(84)90161-7.

PMID: 6427034

14.

Preliminary note: effect of microtubule inhibitors with acrylophenone structure on Triton WR 1339 induced hyperlipidemia in rats.

Brunet C, Luyckx M, Cazin M, Chaoui A, Lesieur I, Lesieur D, Delacourte A.

Methods Find Exp Clin Pharmacol. 1984 May;6(5):227-30.

PMID: 6471968

15.

2-(4-methyl-1-piperazinylmethyl) acrylophenone dihydrochloride: a new antimicrotubular drug.

Mallevais ML, Delacourte A, Lesieur I, Lesieur D, Cazin M, Brunet C, Luyckx M.

Biochimie. 1984 Jun;66(6):477-82. doi: 10.1016/0300-9084(84)90083-x.

PMID: 6498230

16.

Antimicrotubular effects of ethacrynic acid.

Mallevais ML, Delacourte A, Luyckx M, Cazin M, Brunet C, Lesieur D.

Methods Find Exp Clin Pharmacol. 1984 Nov;6(11):675-7.

PMID: 6530905

17.

Anti-PHF antibodies: an immunohistochemical marker of the lesions of the Alzheimer's disease. Characterization and comparison with Bodian's silver impregnation.

Persuy P, Defossez A, Delacourte A, Tramu G, Bouchez B, Arnott G.

Virchows Arch A Pathol Anat Histopathol. 1985;407(1):13-23. doi: 10.1007/BF00701325.

PMID: 2409667

18.

Comparative studies of the neurofilament triplet protein peptide mapping by chemical cleavage.

Richard C, Mahboub S, Delacourte A, Hemon B, Han KK.

Comp Biochem Physiol B. 1985;80(4):707-12. doi: 10.1016/0305-0491(85)90449-3.

PMID: 3922670

19.

Normolipemic activities of acrylophenone derivatives with antimicrotubular properties.

Bard JM, Luyckx M, Brunet C, Cazin M, Fruchart JC, Clavey V, Lesieur I, Lesieur D, Delacourte A.

Methods Find Exp Clin Pharmacol. 1985 Apr;7(4):183-7.

PMID: 4021650

20.

Pharmacological study of nine antimicrotubular drugs with acrylophenone structure on Triton WR 1339-induced hyperlipidemia in rats.

Brunet C, Luyckx M, Cazin M, Lesieur I, Lesieur D, Lespagnol C, Delacourte A, Mallevais ML.

Methods Find Exp Clin Pharmacol. 1985 Nov;7(11):579-83.

PMID: 4087977

21.

Sequence homology analysis of proteins by chemical cleavages: using a mono and two dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

Han KK, Richard C, Zhang GY, Delacourte A.

Int J Biochem. 1986;18(12):1073-82. doi: 10.1016/0020-711x(86)90080-7.

PMID: 2434370 Review.

22.

[Biochemical characterization of an immune serum which specifically marks neurons in neurofibrillary degeneration in Alzheimer's disease].

Delacourte A, Défossez A.

C R Acad Sci III. 1986;303(11):439-44.

PMID: 3096503 French.

23.

Biochemical and immunological studies of bovine and porcine neurofilament triplet proteins by peptide mapping after cyanogen bromide cleavage.

Mahboub S, Hemon B, Defossez A, Delacourte A, Han KK.

Comp Biochem Physiol B. 1986;85(2):299-306. doi: 10.1016/0305-0491(86)90004-0.

PMID: 3096630

24.

Chemical and pharmacological studies of 2-(amino-methyl)acrylophenones.

Lesieur I, Lesieur D, Lespagnol C, Cazin M, Brunet C, Luyckx M, Mallevais ML, Delacourte A, Dubreuil L, Devos J, et al.

Arzneimittelforschung. 1986;36(1):20-4.

PMID: 3954819

25.

Applications of chemical cleavage procedures to the peptide mapping of neurofilament triplet protein bands in sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

Mahboub S, Richard C, Delacourte A, Han KK.

Anal Biochem. 1986 Apr;154(1):171-82. doi: 10.1016/0003-2697(86)90511-7.

PMID: 3085540

26.

[Immunohistochemical study of the basic lesions of Alzheimer's disease].

Defossez A, Persuy P, Tramu G, Delacourte A.

Encephale. 1986 Jul-Aug;12(4):161-8.

PMID: 3539580 French.

27.

Alzheimer's disease: Tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments.

Delacourte A, Defossez A.

J Neurol Sci. 1986 Dec;76(2-3):173-86. doi: 10.1016/0022-510x(86)90167-x.

PMID: 3098926

28.

Observation of morphological relationships between angiopathic blood vessels and degenerative neurites in Alzheimer's disease.

Delacourte A, Defossez A, Persuy P, Peers MC.

Virchows Arch A Pathol Anat Histopathol. 1987;411(3):199-204. doi: 10.1007/BF00735024.

PMID: 2441514

29.

[Immunocytochemical study at the ultrastructural level of neurofibrillary degeneration in Alzheimer's disease].

Defossez A, el Hachimi K, Beauvillain JC, Perre J, Delacourte A, Foncin JF.

C R Acad Sci III. 1987;304(9):217-22.

PMID: 3102001 French.

30.

Chemical modification of thiol group(s) in protein: application to the study of anti-microtubular drugs binding.

Han KK, Delacourte A, Hemon B.

Comp Biochem Physiol B. 1987;88(4):1057-65. doi: 10.1016/0305-0491(87)90005-8.

PMID: 3322663 Review.

31.

 

32.

The effect of 2-(4-methyl-1-piperazinylmethyl) acrylophenone dihydrochloride on the alkylation of tubulin.

Luduena RF, Roach MC, Trcka PP, Mallevais ML, MacRae T.

Arch Biochem Biophys. 1987 Jun;255(2):453-9. doi: 10.1016/0003-9861(87)90414-0.

PMID: 3592685

33.

Transformation of degenerating neurofibrils into amyloid substance in Alzheimer's disease: histochemical and immunohistochemical studies.

Défossez A, Delacourte A.

J Neurol Sci. 1987 Oct;81(1):1-10. doi: 10.1016/0022-510x(87)90179-1.

PMID: 2445923

34.

Alzheimer's disease: a new evidence for common epitopes between microtubule associated protein Tau and paired helical filaments (PHF): demonstration at the electron microscope level by a double immunogold labelling.

Defossez A, Beauvillain JC, Delacourte A, Mazzuca M.

Virchows Arch A Pathol Anat Histopathol. 1988;413(2):141-5. doi: 10.1007/BF00749675.

PMID: 2455379

35.

[Alzheimer's disease: study of the distribution of tau proteins constituting helical filament pairs in human central nervous tissue].

Parent M, Delacourte A, Défossez A, Hémon B, Han KK, Petit H.

C R Acad Sci III. 1988;306(13):391-7.

PMID: 3136867 French.

36.

Cortical angiopathy in Alzheimer's disease: the formation of dystrophic perivascular neurites is related to the exudation of amyloid fibrils from the pathological vessels.

Peers MC, Lenders MB, Défossez A, Delacourte A, Mazzuca M.

Virchows Arch A Pathol Anat Histopathol. 1988;414(1):15-20. doi: 10.1007/BF00749733.

PMID: 3144799

37.

Expression of ETS proto-oncogenes in astrocytes in human cortex.

Amouyel P, Gégonne A, Delacourte A, Défossez A, Stéhelin D.

Brain Res. 1988 Apr 26;447(1):149-53. doi: 10.1016/0006-8993(88)90976-6.

PMID: 3289683

38.

Preferential localization of copper zinc superoxide dismutase in the vulnerable cortical neurons in Alzheimer's disease.

Delacourte A, Defossez A, Ceballos I, Nicole A, Sinet PM.

Neurosci Lett. 1988 Oct 17;92(3):247-53. doi: 10.1016/0304-3940(88)90597-6.

PMID: 3200483

39.

[Direct demonstration of abnormal phosphorylation of Tau microtubular proteins in Alzheimer's disease].

Flament S, Delacourte A, Hemon B, Defossez A.

C R Acad Sci III. 1989;308(3):77-82.

PMID: 2493316 French.

40.

[Alzheimer's disease: the glial reaction is general and severe in all areas of the central nervous system].

Delacourte A, Buée L.

C R Acad Sci III. 1989;308(13):359-65.

PMID: 2496895 French.

41.

[Alzheimer's disease: immunohistochemical characterization of cerebral amyloid deposits].

Behrouz N, Defossez A, Delacourte A, Hublau P, Mazzuca M.

C R Acad Sci III. 1989;308(16):437-44.

PMID: 2543486 French.

42.

Dystrophic peptidergic neurites in senile plaques of Alzheimer's disease hippocampus precede formation of paired helical filaments.

Lenders MB, Peers MC, Tramu G, Delacourte A, Defossez A, Petit H, Mazzuca M.

Brain Res. 1989 Mar 6;481(2):344-9. doi: 10.1016/0006-8993(89)90812-3.

PMID: 2497927

43.

Abnormal tau species are produced during Alzheimer's disease neurodegenerating process.

Flament S, Delacourte A.

FEBS Lett. 1989 Apr 24;247(2):213-6. doi: 10.1016/0014-5793(89)81337-7.

PMID: 2497028

44.

[Alzheimer's disease: tau microtubular protein and beta protein A4 constitute 2 different types of amyloid substance].

Delacourte A, Flament S, Behrouz N, Defossez A.

Acta Neurol Belg. 1989 May-Oct;89(3-4):274-5.

PMID: 2516977 French. No abstract available.

45.

Dystrophic neuropeptidergic neurites in senile plaques of Alzheimer's disease precede formation of paired helical filaments.

Lenders MB, Peers MC, Tramu G, Delacourte A, Defossez A, Petit H, Mazzuca M.

Acta Neurol Belg. 1989 May-Oct;89(3-4):279-85.

PMID: 2516978

46.

Alzheimer's disease: microtubule-associated proteins 2 (MAP 2) are not components of paired helical filaments.

Rosemblatt M, Fellous A, Mazie JC, Delacourte A, Defossez A.

FEBS Lett. 1989 Jul 31;252(1-2):91-4. doi: 10.1016/0014-5793(89)80895-6.

PMID: 2759234

47.

Characterization of two pathological tau protein, variants in Alzheimer brain cortices.

Flament S, Delacourte A, Hémon B, Défossez A.

J Neurol Sci. 1989 Sep;92(2-3):133-41. doi: 10.1016/0022-510x(89)90131-7.

PMID: 2509637

48.

Immunocytochemical profile of neurofibrillary tangles in Down's syndrome patients of different ages.

Mann DM, Prinja D, Davies CA, Ihara Y, Delacourte A, Défossez A, Mayer RJ, Landon M.

J Neurol Sci. 1989 Sep;92(2-3):247-60. doi: 10.1016/0022-510x(89)90140-8.

PMID: 2553874

49.

Alzheimer's disease: glycolytic pretreatment dramatically enhances immunolabeling of senile plaques and cerebrovascular amyloid substance.

Behrouz N, Defossez A, Delacourte A, Hublau P, Mazzuca M.

Lab Invest. 1989 Nov;61(5):576-83.

PMID: 2478759

50.

Qualitative and quantitative comparison of brain proteins in Alzheimer's disease.

Buee L, Laine A, Delacourte A, Flament S, Han KK.

Biol Chem Hoppe Seyler. 1989 Nov;370(11):1229-34. doi: 10.1515/bchm3.1989.370.2.1229.

PMID: 2514723

51.

An antiserum to the N-terminal subsequence of the Alzheimer amyloid beta protein does not react with neurofibrillary tangles.

Behrouz N, Defossez A, Delacourte A, Hublau P, Mazzuca M.

J Gerontol. 1989 Nov;44(6):B156-9. doi: 10.1093/geronj/44.6.b156.

PMID: 2681356

52.

[Alzheimer's disease: the beta amyloid protein A4 is also present in the cortical white matter].

Behrouz N, Defossez A, Delacourte A, Mazzuca M.

C R Acad Sci III. 1990;310(11):539-44.

PMID: 2114194 French.

53.

Pathological proteins Tau 64 and 69 are specifically expressed in the somatodendritic domain of the degenerating cortical neurons during Alzheimer's disease. Demonstration with a panel of antibodies against Tau proteins.

Delacourte A, Flament S, Dibe EM, Hublau P, Sablonnière B, Hémon B, Shérrer V, Défossez A.

Acta Neuropathol. 1990;80(2):111-7. doi: 10.1007/BF00308912.

PMID: 2117840

54.

Correlation between microscopical changes and Tau 64 and 69 biochemical detection in senile dementia of the Alzheimer type. Tau 64 and 69 are reliable markers of the neurofibrillary degeneration.

Flament S, Delacourte A, Delaère P, Duyckaerts C, Hauw JJ.

Acta Neuropathol. 1990;80(2):212-5. doi: 10.1007/BF00308927.

PMID: 2117842

55.

[Experimental approach to neuronal degeneration].

Delacourte A.

C R Seances Soc Biol Fil. 1990;184(1):5-17.

PMID: 2150782 Review. French. No abstract available.

56.

Parkinson's disease and Alzheimer's disease: neurodegenerative disorders due to brain antioxidant system deficiency?

Ceballos I, Javoy-Agid F, Delacourte A, Defossez A, Nicole A, Sinet PM.

Adv Exp Med Biol. 1990;264:493-8. doi: 10.1007/978-1-4684-5730-8_75.

PMID: 2244530 Review. No abstract available.

57.

General and dramatic glial reaction in Alzheimer brains.

Delacourte A.

Neurology. 1990 Jan;40(1):33-7. doi: 10.1212/wnl.40.1.33.

PMID: 2296379

58.

[Towards the development of an in vivo study model of Alzheimer-type neurofibrillary degeneration].

Delacourte A, Flament S, Defossez A.

Presse Med. 1990 Feb 3;19(4):170-3.

PMID: 2137602 French.

59.

Cortical beta-amyloid.

Behrouz N, Defossez A, Delacourte A, Mazzuca M.

Nature. 1990 Apr 5;344(6266):497. doi: 10.1038/344497a0.

PMID: 2181318 No abstract available.

60.

Phosphorylation of Tau proteins: a major event during the process of neurofibrillary degeneration. A comparative study between Alzheimer's disease and Down's syndrome.

Flament S, Delacourte A, Mann DM.

Brain Res. 1990 May 14;516(1):15-9. doi: 10.1016/0006-8993(90)90891-e.

PMID: 2142011

61.

Tau marker?

Flament S, Delacourte A.

Nature. 1990 Jul 5;346(6279):22. doi: 10.1038/346022a0.

PMID: 2114549 No abstract available.

62.

Expression of human Cu-Zn superoxide dismutase gene in transgenic mice: model for gene dosage effect in Down syndrome.

Ceballos I, Nicole A, Briand P, Grimber G, Delacourte A, Flament S, Blouin JL, Thevenin M, Kamoun P, Sinet PM.

Free Radic Res Commun. 1991;12-13 Pt 2:581-9. doi: 10.3109/10715769109145833.

PMID: 1829430

63.

Abnormal Tau proteins in progressive supranuclear palsy. Similarities and differences with the neurofibrillary degeneration of the Alzheimer type.

Flament S, Delacourte A, Verny M, Hauw JJ, Javoy-Agid F.

Acta Neuropathol. 1991;81(6):591-6. doi: 10.1007/BF00296367.

PMID: 1831952

64.

Could Wallerian degeneration contribute to "leuko-araiosis" in subjects free of any vascular disorder?

Leys D, Pruvo JP, Parent M, Vermersch P, Soetaert G, Steinling M, Delacourte A, Défossez A, Rapoport A, Clarisse J, et al.

J Neurol Neurosurg Psychiatry. 1991 Jan;54(1):46-50. doi: 10.1136/jnnp.54.1.46.

PMID: 2010759 Free PMC article.

65.

Neuronal localization of copper-zinc superoxide dismutase protein and mRNA within the human hippocampus from control and Alzheimer's disease brains.

Ceballos I, Javoy-Agid F, Delacourte A, Defossez A, Lafon M, Hirsch E, Nicole A, Sinet PM, Agid Y.

Free Radic Res Commun. 1991;12-13 Pt 2:571-80. doi: 10.3109/10715769109145832.

PMID: 2060834

66.

Are alpha-1-antichymotrypsin and inter-alpha-trypsin inhibitor peripheral markers of Alzheimer's disease?

Furby A, Leys D, Delacourte A, Buee L, Soetaert G, Petit H.

J Neurol Neurosurg Psychiatry. 1991 May;54(5):469. doi: 10.1136/jnnp.54.5.469.

PMID: 1713952 Free PMC article. No abstract available.

67.

Optimization of an alcian blue dot-blot assay for the detection of glycosaminoglycans and proteoglycans.

Buee L, Boyle NJ, Zhang LB, Delacourte A, Fillit HM.

Anal Biochem. 1991 Jun;195(2):238-42. doi: 10.1016/0003-2697(91)90323-l.

PMID: 1750673

68.

[Brain lesions in Alzheimer's disease: contribution of ultrastructural observations].

Defossez A, Delacourte A, Mazzuca M.

Bull Assoc Anat (Nancy). 1991 Jun;75(229):89-92.

PMID: 1777725 French. No abstract available.

69.

Neuronal-specific expression of human copper-zinc superoxide dismutase gene in transgenic mice: animal model of gene dosage effects in Down's syndrome.

Ceballos-Picot I, Nicole A, Briand P, Grimber G, Delacourte A, Defossez A, Javoy-Agid F, Lafon M, Blouin JL, Sinet PM.

Brain Res. 1991 Jun 28;552(2):198-214. doi: 10.1016/0006-8993(91)90084-9.

PMID: 1717112

70.

The immunohistochemical evidence of amyloid diffuse deposits as a pathological hallmark in Alzheimer's disease.

Behrouz N, Defossez A, Delacourte A, Mazzuca M.

J Gerontol. 1991 Nov;46(6):B209-12. doi: 10.1093/geronj/46.6.b209.

PMID: 1719062

71.

Differential distribution of neurofibrillary tangles in the cerebral cortex of dementia pugilistica and Alzheimer's disease cases.

Hof PR, Bouras C, Buée L, Delacourte A, Perl DP, Morrison JH.

Acta Neuropathol. 1992;85(1):23-30. doi: 10.1007/BF00304630.

PMID: 1285493

72.

Mapping of neurofibrillary degeneration in Alzheimer's disease: evaluation of heterogeneity using the quantification of abnormal tau proteins.

Vermersch P, Frigard B, Delacourte A.

Acta Neuropathol. 1992;85(1):48-54. doi: 10.1007/BF00304633.

PMID: 1285496

73.

A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer's disease.

Vallet PG, Guntern R, Hof PR, Golaz J, Delacourte A, Robakis NK, Bouras C.

Acta Neuropathol. 1992;83(2):170-8. doi: 10.1007/BF00308476.

PMID: 1373017

74.

Distribution of cortical neurofibrillary tangles in progressive supranuclear palsy: a quantitative analysis of six cases.

Hof PR, Delacourte A, Bouras C.

Acta Neuropathol. 1992;84(1):45-51. doi: 10.1007/BF00427214.

PMID: 1502881

75.

[Multiple cerebral hemorrhage and amyloid angiopathy of the white matter in a case of Alzheimer's disease].

Lucas C, Parent M, Delandsheer E, Delacourte A, Fournier Y, Défossez A, Leys D.

Rev Neurol (Paris). 1992;148(3):218-20.

PMID: 1604138 Review. French.

76.

Alzheimer's--a correction.

Crawford F, Chartier-Harlin MC, Mullan M, Hardy J, Delacourte A, Arnott G.

Nature. 1992 Apr 2;356(6368):390. doi: 10.1038/356390b0.

PMID: 1557118 No abstract available.

77.

Distribution of neurofibrillary tangles and senile plaques in the cerebral cortex in postencephalitic parkinsonism.

Hof PR, Charpiot A, Delacourte A, Buée L, Purohit D, Perl DP, Bouras C.

Neurosci Lett. 1992 May 11;139(1):10-4. doi: 10.1016/0304-3940(92)90846-y.

PMID: 1407674

78.

Tau antigenic changes induced by glutamate in rat primary culture model: a biochemical approach.

Sautière PE, Sindou P, Couratier P, Hugon J, Wattez A, Delacourte A.

Neurosci Lett. 1992 Jun 22;140(2):206-10. doi: 10.1016/0304-3940(92)90104-f.

PMID: 1354342

79.

Evidence for early vulnerability of the medial and inferior aspects of the temporal lobe in an 82-year-old patient with preclinical signs of dementia. Regional and laminar distribution of neurofibrillary tangles and senile plaques.

Hof PR, Bierer LM, Perl DP, Delacourte A, Buée L, Bouras C, Morrison JH.

Arch Neurol. 1992 Sep;49(9):946-53. doi: 10.1001/archneur.1992.00530330070019.

PMID: 1520086

80.

Presence of abnormally phosphorylated Tau proteins in the entorhinal cortex of aged non-demented subjects.

Vermersch P, Frigard B, David JP, Fallet-Bianco C, Delacourte A.

Neurosci Lett. 1992 Sep 14;144(1-2):143-6. doi: 10.1016/0304-3940(92)90736-q.

PMID: 1436694

81.

Immunohistochemical identification of thrombospondin in normal human brain and in Alzheimer's disease.

Buée L, Hof PR, Roberts DD, Delacourte A, Morrison JH, Fillit HM.

Am J Pathol. 1992 Oct;141(4):783-8.

PMID: 1415477 Free PMC article.

82.

Progressive transformation of the cytoskeleton associated with normal aging and Alzheimer's disease.

Vickers JC, Delacourte A, Morrison JH.

Brain Res. 1992 Oct 30;594(2):273-8. doi: 10.1016/0006-8993(92)91134-z.

PMID: 1450952

83.

[Detection of Alzheimer type pathological epitopes on Tau proteins of neuroblastoma cells after treatment with okadaic acid].

Sautière PE, Caillet-Boudin ML, Wattez A, Buée-Scherrer V, Delacourte A.

C R Acad Sci III. 1993;316(5):533-5.

PMID: 7693312 French.

84.

[Antigenic changes of Tau protein induced by glutamate on primary cultures of neurons: immunocytochemistry study].

Sindou P, Sautiere PE, Couratier P, Delacourte A, Hugon J.

C R Seances Soc Biol Fil. 1993;187(1):87-95.

PMID: 8242426 French.

85.

Binding of secreted human neuroblastoma proteoglycans to the Alzheimer's amyloid A4 peptide.

Buée L, Ding W, Delacourte A, Fillit H.

Brain Res. 1993 Jan 22;601(1-2):154-63. doi: 10.1016/0006-8993(93)91706-x.

PMID: 8431762

86.

Electrophysiological effects of 25-35 amyloid-beta-protein on guinea-pig lateral septal neurons.

Carette B, Poulain P, Delacourte A.

Neurosci Lett. 1993 Mar 5;151(1):111-4. doi: 10.1016/0304-3940(93)90059-t.

PMID: 8385758

87.

General cortical involvement in a late-onset case of Alzheimer disease. A biochemical approach by quantitation of abnormal tau proteins.

Vermersch P, Sautière PE, Goudemand M, Delacourte A.

Mol Chem Neuropathol. 1993 Apr;18(3):213-24. doi: 10.1007/BF03160115.

PMID: 8507301

88.

[Physiopathological bases of Alzheimer disease].

Delacourte A.

Therapie. 1993 May-Jun;48(3):177-83.

PMID: 8140554 French.

89.

Dementia in Parkinson's disease: biochemical evidence for cortical involvement using the immunodetection of abnormal Tau proteins.

Vermersch P, Delacourte A, Javoy-Agid F, Hauw JJ, Agid Y.

Ann Neurol. 1993 May;33(5):445-50. doi: 10.1002/ana.410330506.

PMID: 8498822

90.

Binding of vascular heparan sulfate proteoglycan to Alzheimer's amyloid precursor protein is mediated in part by the N-terminal region of A4 peptide.

Buée L, Ding W, Anderson JP, Narindrasorasak S, Kisilevsky R, Boyle NJ, Robakis NK, Delacourte A, Greenberg B, Fillit HM.

Brain Res. 1993 Nov 12;627(2):199-204. doi: 10.1016/0006-8993(93)90321-d.

PMID: 8298962

91.

Amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam: quantitative neuropathology, immunohistochemical analysis of neuronal vulnerability, and comparison with related neurodegenerative disorders.

Hof PR, Nimchinsky EA, Buée-Scherrer V, Buée L, Nasrallah J, Hottinger AF, Purohit DP, Loerzel AJ, Steele JC, Delacourte A, et al.

Acta Neuropathol. 1994;88(5):397-404. doi: 10.1007/BF00389490.

PMID: 7847067

92.

Pathological Tau proteins of Alzheimer's disease as a biochemical marker of neurofibrillary degeneration.

Delacourte A.

Biomed Pharmacother. 1994;48(7):287-95. doi: 10.1016/0753-3322(94)90174-0.

PMID: 7858159 Review.

93.

[Subcortical dementia of the Neumann type. Contribution of diagnostic imaging].

Vermersch P, Daems-Monpeurt C, Parent M, Pruvo JP, Delacourte A, Petit H.

Rev Neurol (Paris). 1994;150(5):354-8.

PMID: 7878321 French.

94.

Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders.

Buée L, Hof PR, Bouras C, Delacourte A, Perl DP, Morrison JH, Fillit HM.

Acta Neuropathol. 1994;87(5):469-80. doi: 10.1007/BF00294173.

PMID: 8059599

95.

Biochemical mapping of neurofibrillary degeneration in a case of progressive supranuclear palsy: evidence for general cortical involvement.

Vermersch P, Robitaille Y, Bernier L, Wattez A, Gauvreau D, Delacourte A.

Acta Neuropathol. 1994;87(6):572-7. doi: 10.1007/BF00293317.

PMID: 8091949

96.

[Normal cerebral aging: study of glial reaction].

David JP, Fallet-Bianco C, Vermersch P, Frigard B, Di Menza C, Delacourte A.

C R Acad Sci III. 1994 Aug;317(8):749-53.

PMID: 7882158 French.

97.

Alterations in neurofilament protein immunoreactivity in human hippocampal neurons related to normal aging and Alzheimer's disease.

Vickers JC, Riederer BM, Marugg RA, Buée-Scherrer V, Buée L, Delacourte A, Morrison JH.

Neuroscience. 1994 Sep;62(1):1-13. doi: 10.1016/0306-4522(94)90310-7.

PMID: 7816192

98.

Dementia in the oldest-old: quantitative analysis of 12 cases from a psychiatric hospital.

Giannakopoulos P, Hof PR, Giannakopoulos AS, Buée-Scherrer V, Surini M, Delacourte A, Bouras C.

Dementia. 1994 Nov-Dec;5(6):348-56. doi: 10.1159/000106745.

PMID: 7866489

99.

Immunocytochemical characterization of Tau proteins during cerebral aging of the lemurian primate Microcebus murinus.

Bons N, Jallageas V, Silhol S, Mestre-Frances N, Petter A, Delacourte A.

C R Acad Sci III. 1995 Jan;318(1):77-83.

PMID: 7757807

100.

Biochemical characterization of Tau proteins during cerebral aging of the lemurian primate Microcebus murinus.

Delacourte A, Sautière PE, Wattez A, Mourton-Gilles C, Petter A, Bons N.

C R Acad Sci III. 1995 Jan;318(1):85-9.

PMID: 7757808

101.

Immunogold labelling of paired helical filaments and amyloid fibrils by specific monoclonal and polyclonal antibodies.

Reig S, Buée-Scherrer V, Mourton-Gilles C, Defossez A, Delacourte A, Beauvillain JC, Mazzuca M.

Acta Neuropathol. 1995;90(5):441-7. doi: 10.1007/BF00294803.

PMID: 8560975

102.

Shift from fetal-type to Alzheimer-type phosphorylated Tau proteins in SKNSH-SY 5Y cells treated with okadaic acid.

Dupont-Wallois L, Sautière PE, Cocquerelle C, Bailleul B, Delacourte A, Caillet-Boudin ML.

FEBS Lett. 1995 Jan 3;357(2):197-201. doi: 10.1016/0014-5793(94)01361-4.

PMID: 7805890

103.

[Demonstration of a specific profile of pathological Tau proteins in frontotemporal dementia cases].

Vermersch P, Bordet R, Ledoze F, Ruchoux MM, Chapon F, Thomas P, Destée A, Lechevallier B, Delacourte A.

C R Acad Sci III. 1995 Apr;318(4):439-45.

PMID: 7648357 French.

104.

Neurofibrillary degeneration in amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam. Immunochemical characterization of tau proteins.

Buée-Scherrer V, Buée L, Hof PR, Leveugle B, Gilles C, Loerzel AJ, Perl DP, Delacourte A.

Am J Pathol. 1995 Apr;146(4):924-32.

PMID: 7717459 Free PMC article.

105.

New immunoassay for the mapping of neurofibrillary degeneration in Alzheimer's disease using two monoclonal antibodies against human paired helical filament tau proteins.

Condamines O, Buée-Scherrer V, Boissier L, Wattez A, Delacourte A, Pau B, Mourton-Gilles C.

Neurosci Lett. 1995 Jun 9;192(2):81-4. doi: 10.1016/0304-3940(95)11617-6.

PMID: 7675326

106.

Immunocytochemical characterization of Tau proteins during cerebral aging of the lemurian primate Microcebus murinus.

Bons N, Jallageas V, Silhol S, Mestre-Frances N, Petter A, Delacourte A.

C R Acad Sci III. 1995 Jul;318(7):741-7.

PMID: 7583762

107.

Alzheimer's disease: A beta or ApoE amyloidosis?

Buée L, Permanne B, Pérez-Tur J, Chartier-Harlin MC, Delacourte A.

Lancet. 1995 Jul 1;346(8966):59. doi: 10.1016/s0140-6736(95)92694-1.

PMID: 7603172 No abstract available.

108.

Quantitation of Alzheimer's amyloid peptide and identification of related amyloid proteins by dot-blot immunoassay.

Permanne B, Buée L, David JP, Fallet-Bianco C, Di Menza C, Delacourte A.

Brain Res. 1995 Jul 10;685(1-2):154-62. doi: 10.1016/0006-8993(95)00431-o.

PMID: 7583241

109.

Cortical mapping of Alzheimer pathology in brains of aged non-demented subjects.

Vermersch P, David JP, Frigard B, Fallet-Bianco C, Wattez A, Petit H, Delacourte A.

Prog Neuropsychopharmacol Biol Psychiatry. 1995 Oct;19(6):1035-47. doi: 10.1016/0278-5846(95)00195-6.

PMID: 8584681

110.

Isoelectric point differentiates PHF-tau from biopsy-derived human brain tau proteins.

Sergeant N, Bussière T, Vermersch P, Lejeune JP, Delacourte A.

Neuroreport. 1995 Nov 13;6(16):2217-20. doi: 10.1097/00001756-199511000-00028.

PMID: 8595206

111.

Evidence for apolipoprotein E epsilon 4 association in early-onset Alzheimer's patients with late-onset relatives.

Pérez-Tur J, Campion D, Martinez M, Brice A, Tardieu S, Hannequin D, Agid Y, Delacourte A, Clerget-Darpoux F, Chartier-Harlin MC.

Am J Med Genet. 1995 Dec 18;60(6):550-3. doi: 10.1002/ajmg.1320600613.

PMID: 8825894

112.

Apolipoprotein E in Guamanian amyotrophic lateral sclerosis/parkinsonism-dementia complex: genotype analysis and relationships to neuropathological changes.

Buée L, Pérez-Tur J, Leveugle B, Buée-Scherrer V, Mufson EJ, Loerzel AJ, Chartier-Harlin MC, Perl DP, Delacourte A, Hof PR.

Acta Neuropathol. 1996;91(3):247-53. doi: 10.1007/s004010050422.

PMID: 8834536

113.

Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick's disease.

Buée Scherrer V, Hof PR, Buée L, Leveugle B, Vermersch P, Perl DP, Olanow CW, Delacourte A.

Acta Neuropathol. 1996;91(4):351-9. doi: 10.1007/s004010050436.

PMID: 8928611

114.

Phorbol ester enhances phosphorylated tau protein immunoreactivity in neuronal cultures.

Couratier P, Lesort M, Condamines O, Mourton-Gilles C, Delacourte A, Hugon J.

Neurosci Lett. 1996 Jan 26;203(3):155-8. doi: 10.1016/0304-3940(96)12302-8.

PMID: 8742016

115.

Specific pathological Tau protein variants characterize Pick's disease.

Delacourte A, Robitaille Y, Sergeant N, Buée L, Hof PR, Wattez A, Laroche-Cholette A, Mathieu J, Chagnon P, Gauvreau D.

J Neuropathol Exp Neurol. 1996 Feb;55(2):159-68. doi: 10.1097/00005072-199602000-00004.

PMID: 8786374

116.

Dephosphorylation studies of SKNSH-SY 5Y cell Tau proteins by endogenous phosphatase activity.

Soulié C, Lépagnol J, Delacourte A, Caillet-Boudin ML.

Neurosci Lett. 1996 Mar 15;206(2-3):189-92. doi: 10.1016/s0304-3940(96)12472-1.

PMID: 8710183

117.

AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease.

Buée-Scherrer V, Condamines O, Mourton-Gilles C, Jakes R, Goedert M, Pau B, Delacourte A.

Brain Res Mol Brain Res. 1996 Jul;39(1-2):79-88. doi: 10.1016/0169-328x(96)00003-4.

PMID: 8804716

118.

Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease.

Lefranc D, Vermersch P, Dallongeville J, Daems-Monpeurt C, Petit H, Delacourte A.

Neurosci Lett. 1996 Jul 12;212(2):91-4. doi: 10.1016/0304-3940(96)12774-9.

PMID: 8832646

119.

Specific tau variants in the brains of patients with myotonic dystrophy.

Vermersch P, Sergeant N, Ruchoux MM, Hofmann-Radvanyi H, Wattez A, Petit H, Dwailly P, Delacourte A.

Neurology. 1996 Sep;47(3):711-7. doi: 10.1212/wnl.47.3.711.

PMID: 8797469

120.

Analysis of the APOE alleles impact in Down's syndrome.

Lambert JC, Pérez-Tur J, Dupire MJ, Delacourte A, Frigard B, Chartier-Harlin MC.

Neurosci Lett. 1996 Dec 6;220(1):57-60. doi: 10.1016/s0304-3940(96)13244-4.

PMID: 8977148

121.

Induction of a specific tau Alzheimer epitope in SY-5Y neuroblastoma cells.

Caillet-Boudin ML, Delacourte A.

Neuroreport. 1996 Dec 20;8(1):307-10. doi: 10.1097/00001756-199612200-00061.

PMID: 9051801

122.

Normal and pathological Tau proteins as factors for microtubule assembly.

Delacourte A, Buée L.

Int Rev Cytol. 1997;171:167-224. doi: 10.1016/s0074-7696(08)62588-7.

PMID: 9066128 Review.

123.

ApoE synthesis in human neuroblastoma cells.

Dupont-Wallois L, Soulié C, Sergeant N, Wavrant-de Wrieze N, Chartier-Harlin MC, Delacourte A, Caillet-Boudin ML.

Neurobiol Dis. 1997;4(5):356-64. doi: 10.1006/nbdi.1997.0155.

PMID: 9440124

124.

Association between the low density lipoprotein receptor-related protein (LRP) and Alzheimer's disease.

Wavrant-DeVrièze F, Pérez-Tur J, Lambert JC, Frigard B, Pasquier F, Delacourte A, Amouyel P, Hardy J, Chartier-Harlin MC.

Neurosci Lett. 1997 May 9;227(1):68-70. doi: 10.1016/s0304-3940(97)00304-2.

PMID: 9178861

125.

Two-dimensional characterization of paired helical filament-tau from Alzheimer's disease: demonstration of an additional 74-kDa component and age-related biochemical modifications.

Sergeant N, David JP, Goedert M, Jakes R, Vermersch P, Buée L, Lefranc D, Wattez A, Delacourte A.

J Neurochem. 1997 Aug;69(2):834-44. doi: 10.1046/j.1471-4159.1997.69020834.x.

PMID: 9231745

126.

Neurofibrillary tangles in Gerstmann-Sträussler-Scheinker syndrome with the A117V prion gene mutation.

Tranchant C, Sergeant N, Wattez A, Mohr M, Warter JM, Delacourte A.

J Neurol Neurosurg Psychiatry. 1997 Aug;63(2):240-6. doi: 10.1136/jnnp.63.2.240.

PMID: 9285466 Free PMC article.

127.

Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases.

Sergeant N, David JP, Lefranc D, Vermersch P, Wattez A, Delacourte A.

FEBS Lett. 1997 Aug 4;412(3):578-82. doi: 10.1016/s0014-5793(97)00859-4.

PMID: 9276470

128.

Pathological tau proteins in postencephalitic parkinsonism: comparison with Alzheimer's disease and other neurodegenerative disorders.

Buée-Scherrer V, Buée L, Leveugle B, Perl DP, Vermersch P, Hof PR, Delacourte A.

Ann Neurol. 1997 Sep;42(3):356-9. doi: 10.1002/ana.410420312.

PMID: 9307257

129.

Brain microvascular changes in Alzheimer's disease and other dementias.

Buée L, Hof PR, Delacourte A.

Ann N Y Acad Sci. 1997 Sep 26;826:7-24. doi: 10.1111/j.1749-6632.1997.tb48457.x.

PMID: 9329677 Review.

130.

Glial reaction in the hippocampal formation is highly correlated with aging in human brain.

David JP, Ghozali F, Fallet-Bianco C, Wattez A, Delaine S, Boniface B, Di Menza C, Delacourte A.

Neurosci Lett. 1997 Oct 10;235(1-2):53-6. doi: 10.1016/s0304-3940(97)00708-8.

PMID: 9389594

131.

Distortion of allelic expression of apolipoprotein E in Alzheimer's disease.

Lambert JC, Pérez-Tur J, Dupire MJ, Galasko D, Mann D, Amouyel P, Hardy J, Delacourte A, Chartier-Harlin MC.

Hum Mol Genet. 1997 Nov;6(12):2151-4. doi: 10.1093/hmg/6.12.2151.

PMID: 9328480

132.

Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylation.

Delacourte A, Sergeant N, Wattez A, Gauvreau D, Robitaille Y.

Ann Neurol. 1998 Feb;43(2):193-204. doi: 10.1002/ana.410430209.

PMID: 9485060

133.

[Diagnosis of Alzheimer's disease].

Delacourte A.

Ann Biol Clin (Paris). 1998 Mar-Apr;56(2):133-42.

PMID: 9754238 Review. French.

134.

Influence and optimisation of operating parameters with a new binder in wet granulation. I: use in powder form.

Soyeux P, Delacourte A, Delie B, Lefevre P, Boniface B.

Eur J Pharm Biopharm. 1998 Jul;46(1):95-103. doi: 10.1016/s0939-6411(97)00162-8.

PMID: 9700027

135.

Apolipoprotein E and Tau phosphorylation in human neuroblastoma cells.

Caillet-Boudin ML, Dupont-Wallois L, Soulié C, Delacourte A.

Neurosci Lett. 1998 Jul 3;250(2):83-6. doi: 10.1016/s0304-3940(98)00448-0.

PMID: 9697924

136.

Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes.

Mailliot C, Sergeant N, Bussière T, Caillet-Boudin ML, Delacourte A, Buée L.

FEBS Lett. 1998 Aug 21;433(3):201-4. doi: 10.1016/s0014-5793(98)00910-7.

PMID: 9744794

137.

Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease.

Lambert JC, Berr C, Pasquier F, Delacourte A, Frigard B, Cottel D, Pérez-Tur J, Mouroux V, Mohr M, Cécyre D, Galasko D, Lendon C, Poirier J, Hardy J, Mann D, Amouyel P, Chartier-Harlin MC.

Hum Mol Genet. 1998 Sep;7(9):1511-6. doi: 10.1093/hmg/7.9.1511.

PMID: 9700208

138.

Non-Alzheimer degenerative dementias.

Pasquier F, Delacourte A.

Curr Opin Neurol. 1998 Oct;11(5):417-27. doi: 10.1097/00019052-199810000-00002.

PMID: 9847989 Review.

139.

Alzheimer-specific epitope of AT100 in transfected cell lines with tau: toward an efficient cell model of tau abnormal phosphorylation.

Mailliot C, Bussière T, Caillet-Boudin ML, Delacourte A, Buée L.

Neurosci Lett. 1998 Oct 9;255(1):13-6. doi: 10.1016/s0304-3940(98)00693-4.

PMID: 9839715

140.

Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele.

Grouselle D, Winsky-Sommerer R, David JP, Delacourte A, Dournaud P, Epelbaum J.

Neurosci Lett. 1998 Oct 9;255(1):21-4. doi: 10.1016/s0304-3940(98)00698-3.

PMID: 9839717

141.

Biochemical and molecular characterization of neurofibrillary degeneration in frontotemporal dementias.

Delacourte A.

Dement Geriatr Cogn Disord. 1999;10 Suppl 1:75-9. doi: 10.1159/000051218.

PMID: 10436346 Review.

142.

A new GTP-cyclohydrolase I mutation in an unusual dopa-responsive dystonia, familial form.

Brique S, Destée A, Lambert JC, Mouroux V, Delacourte A, Amouyel P, Chartier-Harlin MC.

Neuroreport. 1999 Feb 25;10(3):487-91. doi: 10.1097/00001756-199902250-00008.

PMID: 10208576

143.

Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms.

Sergeant N, Wattez A, Delacourte A.

J Neurochem. 1999 Mar;72(3):1243-9. doi: 10.1046/j.1471-4159.1999.0721243.x.

PMID: 10037497

144.

Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration.

Bussière T, Hof PR, Mailliot C, Brown CD, Caillet-Boudin ML, Perl DP, Buée L, Delacourte A.

Acta Neuropathol. 1999 Mar;97(3):221-30. doi: 10.1007/s004010050978.

PMID: 10090668

145.

The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease.

Delacourte A, David JP, Sergeant N, Buée L, Wattez A, Vermersch P, Ghozali F, Fallet-Bianco C, Pasquier F, Lebert F, Petit H, Di Menza C.

Neurology. 1999 Apr 12;52(6):1158-65. doi: 10.1212/wnl.52.6.1158.

PMID: 10214737

146.

Synthesis of apolipoprotein E (ApoE) mRNA by human neuronal-type SK N SH-SY 5Y cells and its regulation by nerve growth factor and ApoE.

Soulié C, Mitchell V, Dupont-Wallois L, Chartier-Harlin MC, Beauvillain JC, Delacourte A, Caillet-Boudin ML.

Neurosci Lett. 1999 Apr 16;265(2):147-50. doi: 10.1016/s0304-3940(99)00167-6.

PMID: 10327190

147.

A novel presenilin-2 splice variant in human Alzheimer's disease brain tissue.

Sato N, Hori O, Yamaguchi A, Lambert JC, Chartier-Harlin MC, Robinson PA, Delacourte A, Schmidt AM, Furuyama T, Imaizumi K, Tohyama M, Takagi T.

J Neurochem. 1999 Jun;72(6):2498-505. doi: 10.1046/j.1471-4159.1999.0722498.x.

PMID: 10349860

148.

Neurodegenerative diseases of Guam: analysis of TAU.

Pérez-Tur J, Buée L, Morris HR, Waring SC, Onstead L, Wavrant-De Vrièze F, Crook R, Buée-Scherrer V, Hof PR, Petersen RC, McGeer PL, Delacourte A, Hutton M, Siddique T, Ahlskog JE, Hardy J, Steele JC.

Neurology. 1999 Jul 22;53(2):411-3. doi: 10.1212/wnl.53.2.411.

PMID: 10430438

149.

Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease.

Buée L, Delacourte A.

Brain Pathol. 1999 Oct;9(4):681-93. doi: 10.1111/j.1750-3639.1999.tb00550.x.

PMID: 10517507 Free PMC article. Review.

150.

Pathological tau phenotypes. The weight of mutations, polymorphisms, and differential neuronal vulnerabilities.

Mailliot C, Bussière T, Hamdane M, Sergeant N, Caillet ML, Delacourte A, Buée L.

Ann N Y Acad Sci. 2000;920:107-14. doi: 10.1111/j.1749-6632.2000.tb06911.x.

PMID: 11193138

151.

Rapid tau protein dephosphorylation and differential rephosphorylation during cardiac arrest-induced cerebral ischemia and reperfusion.

Mailliot C, Podevin-Dimster V, Rosenthal RE, Sergeant N, Delacourte A, Fiskum G, Buée L.

J Cereb Blood Flow Metab. 2000 Mar;20(3):543-9. doi: 10.1097/00004647-200003000-00013.

PMID: 10724119

152.

Research goals in progressive supranuclear palsy. First International Brainstorming Conference on PSP.

Litvan I, Dickson DW, Buttner-Ennever JA, Delacourte A, Hutton M, Dubois B, Golbe LI, Hallett M, Schellenberg GD, Standaert D, Brooks DJ, Price D.

Mov Disord. 2000 May;15(3):446-58.

PMID: 10830408 No abstract available.

153.

[Natural and molecular history of Alzheimer disease].

Delacourte A.

Ann Biol Clin (Paris). 2000 May-Jun;58(3):350-5.

PMID: 10846240 Review. French. No abstract available.

154.

Research goals in progressive supranuclear palsy.

Litvan I, Dickson DW, Buttner-Ennever JA, Delacourte A, Hutton M, Dubois B, Golbe LI, Hallett M, Schellenberg GD, Standaert D, Brooks DJ, Price D.

Mov Disord. 2000 May;15(3):446-458. doi: 10.1002/1531-8257(200005)15:3<446::AID-MDS1005>3.0.CO;2-C.

PMID: 28470736 No abstract available.

155.

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders.

Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR.

Brain Res Brain Res Rev. 2000 Aug;33(1):95-130. doi: 10.1016/s0165-0173(00)00019-9.

PMID: 10967355 Review.

156.

Tau pathology: a marker of neurodegenerative disorders.

Delacourte A, Buée L.

Curr Opin Neurol. 2000 Aug;13(4):371-6. doi: 10.1097/00019052-200008000-00002.

PMID: 10970052 Review.

157.

A double-labeling immunohistochemical study of tau exon 10 in Alzheimer's disease, progressive supranuclear palsy and Pick's disease.

Ishizawa K, Ksiezak-Reding H, Davies P, Delacourte A, Tiseo P, Yen SH, Dickson DW.

Acta Neuropathol. 2000 Sep;100(3):235-44. doi: 10.1007/s004019900177.

PMID: 10965792

158.

Synthesis and regulation of apolipoprotein E during the differentiation of human neuronal precursor NT2/D1 cells into postmitotic neurons.

Ferreira S, Dupire MJ, Delacourte A, Najib J, Caillet-Boudin ML.

Exp Neurol. 2000 Dec;166(2):415-21. doi: 10.1006/exnr.2000.7510.

PMID: 11085906

159.

Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains.

Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG.

EMBO Rep. 2000 Dec;1(6):530-5. doi: 10.1093/embo-reports/kvd107.

PMID: 11263499 Free PMC article.

160.

Neuronal subpopulations and genetic background in tauopathies: a catch 22 story?

Buée L, Delacourte A, Wilhelmsen KC, Miller B, Geschwind D.

Neurobiol Aging. 2001 Jan-Feb;22(1):115-21. doi: 10.1016/s0197-4580(00)00199-8.

PMID: 11164283 No abstract available.

161.

The molecular parameters of tau pathology. Tau as a killer and a witness.

Delacourte A.

Adv Exp Med Biol. 2001;487:5-19. doi: 10.1007/978-1-4615-1249-3_2.

PMID: 11403165 Review. No abstract available.

162.

Hyperphosphorylation of tau is mediated by ERK activation during anticancer drug-induced apoptosis in neuroblastoma cells.

Guise S, Braguer D, Carles G, Delacourte A, Briand C.

J Neurosci Res. 2001 Feb 1;63(3):257-67. doi: 10.1002/1097-4547(20010201)63:3<257::AID-JNR1019>3.0.CO;2-T.

PMID: 11170175

163.

Differential phosphorylation of tau proteins during kitten brain development and Alzheimer's disease.

Riederer BM, Mourton-Gilles C, Frey P, Delacourte A, Probst A.

J Neurocytol. 2001 Feb;30(2):145-58. doi: 10.1023/a:1011991207942.

PMID: 11577253

164.

Sequence of neurofibrillary changes in aging and Alzheimer's disease: A confocal study with phospho-tau antibody, AD2.

Galván M, David JP, Delacourte A, Luna J, Mena R.

J Alzheimers Dis. 2001 Aug;3(4):417-425. doi: 10.3233/jad-2001-3409.

PMID: 12214046

165.

Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1.

Sergeant N, Sablonnière B, Schraen-Maschke S, Ghestem A, Maurage CA, Wattez A, Vermersch P, Delacourte A.

Hum Mol Genet. 2001 Sep 15;10(19):2143-55. doi: 10.1093/hmg/10.19.2143.

PMID: 11590131

166.

Paradoxical phosphorylation of the serine 199 on tau proteins from young individuals.

Maurage CA, Sergeant N, Ruchoux MM, Hauw JJ, Delacourte A.

Neuroreport. 2001 Oct 29;12(15):3177-81. doi: 10.1097/00001756-200110290-00007.

PMID: 11711851

167.

Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats display muscular and brain abnormalities.

Seznec H, Agbulut O, Sergeant N, Savouret C, Ghestem A, Tabti N, Willer JC, Ourth L, Duros C, Brisson E, Fouquet C, Butler-Browne G, Delacourte A, Junien C, Gourdon G.

Hum Mol Genet. 2001 Nov 1;10(23):2717-26. doi: 10.1093/hmg/10.23.2717.

PMID: 11726559

168.

BSE infection of the small short-lived primate Microcebus murinus.

Bons N, Lehmann S, Nishida N, Mestre-Frances N, Dormont D, Belli P, Delacourte A, Grassi J, Brown P.

C R Biol. 2002 Jan;325(1):67-74. doi: 10.1016/s1631-0691(02)01390-2.

PMID: 11862624

169.

[Tau story: from frontotemporal dementia to other tauopathies].

Buée L, Hamdane M, Delobel P, Sambo AV, Bégard S, Ghestem A, Sergeant N, Delacourte A.

J Soc Biol. 2002;196(1):103-8.

PMID: 12134624 Review. French.

170.

Increase of cdk5 is related to neurofibrillary pathology in progressive supranuclear palsy.

Borghi R, Giliberto L, Assini A, Delacourte A, Perry G, Smith MA, Strocchi P, Zaccheo D, Tabaton M.

Neurology. 2002 Feb 26;58(4):589-92. doi: 10.1212/wnl.58.4.589.

PMID: 11865137

171.

Functional characterization of FTDP-17 tau gene mutations through their effects on Xenopus oocyte maturation.

Delobel P, Flament S, Hamdane M, Jakes R, Rousseau A, Delacourte A, Vilain JP, Goedert M, Buée L.

J Biol Chem. 2002 Mar 15;277(11):9199-205. doi: 10.1074/jbc.M107716200. Epub 2001 Dec 26.

PMID: 11756436

172.

Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy.

Caparros-Lefebvre D, Sergeant N, Lees A, Camuzat A, Daniel S, Lannuzel A, Brice A, Tolosa E, Delacourte A, Duyckaerts C.

Brain. 2002 Apr;125(Pt 4):801-11. doi: 10.1093/brain/awf086.

PMID: 11912113

173.

Pathological determinants of the transition to clinical dementia in Alzheimer's disease.

Royall DR, Palmer R, Mulroy AR, Polk MJ, Román GC, David JP, Delacourte A.

Exp Aging Res. 2002 Apr-Jun;28(2):143-62. doi: 10.1080/03610730252800166.

PMID: 11928525

174.

Modelling Alzheimer-specific abnormal Tau phosphorylation independently of GSK3beta and PKA kinase activities.

Delobel P, Flament S, Hamdane M, Delacourte A, Vilain JP, Buée L.

FEBS Lett. 2002 Apr 10;516(1-3):151-5. doi: 10.1016/s0014-5793(02)02525-5.

PMID: 11959122

175.

Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP-CTFs), associated with tau pathology stages, in Alzheimer's disease.

Sergeant N, David JP, Champain D, Ghestem A, Wattez A, Delacourte A.

J Neurochem. 2002 May;81(4):663-72. doi: 10.1046/j.1471-4159.2002.00901.x.

PMID: 12065626

176.

Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease.

Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, Pasquier F, David JP.

Neurology. 2002 Aug 13;59(3):398-407. doi: 10.1212/wnl.59.3.398.

PMID: 12177374

177.

Argyrophilic grain disease and Alzheimer's disease are distinguished by their different distribution of tau protein isoforms.

Tolnay M, Sergeant N, Ghestem A, Chalbot S, De Vos RA, Jansen Steur EN, Probst A, Delacourte A.

Acta Neuropathol. 2002 Oct;104(4):425-34. doi: 10.1007/s00401-002-0591-z. Epub 2002 Jul 26.

PMID: 12200631

178.

Abnormal Tau phosphorylation of the Alzheimer-type also occurs during mitosis.

Delobel P, Flament S, Hamdane M, Mailliot C, Sambo AV, Bégard S, Sergeant N, Delacourte A, Vilain JP, Buée L.

J Neurochem. 2002 Oct;83(2):412-20. doi: 10.1046/j.1471-4159.2002.01143.x.

PMID: 12423251

179.

Tau aggregation in the hippocampal formation: an ageing or a pathological process?

Delacourte A, Sergeant N, Wattez A, Maurage CA, Lebert F, Pasquier F, David JP.

Exp Gerontol. 2002 Oct-Nov;37(10-11):1291-6. doi: 10.1016/s0531-5565(02)00141-9.

PMID: 12470843 Review.

180.

Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients.

Weill-Engerer S, David JP, Sazdovitch V, Liere P, Eychenne B, Pianos A, Schumacher M, Delacourte A, Baulieu EE, Akwa Y.

J Clin Endocrinol Metab. 2002 Nov;87(11):5138-43. doi: 10.1210/jc.2002-020878.

PMID: 12414884

181.

Pin1: a therapeutic target in Alzheimer neurodegeneration.

Hamdane M, Smet C, Sambo AV, Leroy A, Wieruszeski JM, Delobel P, Maurage CA, Ghestem A, Wintjens R, Bégard S, Sergeant N, Delacourte A, Horvath D, Landrieu I, Lippens G, Buée L.

J Mol Neurosci. 2002 Dec;19(3):275-87. doi: 10.1385/JMN:19:3:275.

PMID: 12540053

182.

Association of ATP synthase alpha-chain with neurofibrillary degeneration in Alzheimer's disease.

Sergeant N, Wattez A, Galván-valencia M, Ghestem A, David JP, Lemoine J, Sautiére PE, Dachary J, Mazat JP, Michalski JC, Velours J, Mena-López R, Delacourte A.

Neuroscience. 2003;117(2):293-303. doi: 10.1016/s0306-4522(02)00747-9.

PMID: 12614671

183.

Pathological determinants of dementia in Alzheimer's disease (AD).

Royall DR, Román GC, Delacourte A.

Exp Aging Res. 2003 Jan-Mar;29(1):107-10. doi: 10.1080/03610730303707.

PMID: 12735084 No abstract available.

184.

The neuropathology and biochemistry of frontotemporal dementia.

Munoz DG, Dickson DW, Bergeron C, Mackenzie IR, Delacourte A, Zhukareva V.

Ann Neurol. 2003;54 Suppl 5:S24-8. doi: 10.1002/ana.10571.

PMID: 12833365 Review. No abstract available.

185.

The proprotein convertase PC2 is involved in the maturation of prosomatostatin to somatostatin-14 but not in the somatostatin deficit in Alzheimer's disease.

Winsky-Sommerer R, Grouselle D, Rougeot C, Laurent V, David JP, Delacourte A, Dournaud P, Seidah NG, Lindberg I, Trottier S, Epelbaum J.

Neuroscience. 2003;122(2):437-47. doi: 10.1016/s0306-4522(03)00560-8.

PMID: 14614908

186.

O-GlcNAc glycosylation and neurological disorders.

Lefebvre T, Caillet-Boudin ML, Buée L, Delacourte A, Michalski JC.

Adv Exp Med Biol. 2003;535:189-202. doi: 10.1007/978-1-4615-0065-0_12.

PMID: 14714896 Review. No abstract available.

187.

Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins--a role in nuclear localization.

Lefebvre T, Ferreira S, Dupont-Wallois L, Bussière T, Dupire MJ, Delacourte A, Michalski JC, Caillet-Boudin ML.

Biochim Biophys Acta. 2003 Jan 20;1619(2):167-76. doi: 10.1016/s0304-4165(02)00477-4.

PMID: 12527113

188.

Phosphorylated serine 199 of microtubule-associated protein tau is a neuronal epitope abundantly expressed in youth and an early marker of tau pathology.

Maurage CA, Sergeant N, Ruchoux MM, Hauw JJ, Delacourte A.

Acta Neuropathol. 2003 Feb;105(2):89-97. doi: 10.1007/s00401-002-0608-7. Epub 2002 Sep 7.

PMID: 12536218

189.

In vitro metabolism of dehydroepiandrosterone (DHEA) to 7alpha-hydroxy-DHEA and Delta5-androstene-3beta,17beta-diol in specific regions of the aging brain from Alzheimer's and non-demented patients.

Weill-Engerer S, David JP, Sazdovitch V, Liere P, Schumacher M, Delacourte A, Baulieu EE, Akwa Y.

Brain Res. 2003 Apr 18;969(1-2):117-25. doi: 10.1016/s0006-8993(03)02288-1.

PMID: 12676372

190.

Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice.

Lesné S, Docagne F, Gabriel C, Liot G, Lahiri DK, Buée L, Plawinski L, Delacourte A, MacKenzie ET, Buisson A, Vivien D.

J Biol Chem. 2003 May 16;278(20):18408-18. doi: 10.1074/jbc.M300819200. Epub 2003 Mar 7.

PMID: 12626500

191.

Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach.

Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C, Wattez A, David JP, Vanmechelen E, Sergheraert C, Delacourte A.

J Neurochem. 2003 Jun;85(6):1581-91. doi: 10.1046/j.1471-4159.2003.01818.x.

PMID: 12787077

192.

Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex.

Hamdane M, Sambo AV, Delobel P, Bégard S, Violleau A, Delacourte A, Bertrand P, Benavides J, Buée L.

J Biol Chem. 2003 Sep 5;278(36):34026-34. doi: 10.1074/jbc.M302872200. Epub 2003 Jun 24.

PMID: 12826674

193.

Neurofibrillary degeneration of the Alzheimer-type: an alternate pathway to neuronal apoptosis?

Hamdane M, Delobel P, Sambo AV, Smet C, Bégard S, Violleau A, Landrieu I, Delacourte A, Lippens G, Flament S, Buée L.

Biochem Pharmacol. 2003 Oct 15;66(8):1619-25. doi: 10.1016/s0006-2952(03)00533-1.

PMID: 14555242 Review.

194.

In vitro models of age-related neurodegenerative disorders.

Delacourte A, Sergeant N, Buée L.

Exp Gerontol. 2003 Nov-Dec;38(11-12):1309-17. doi: 10.1016/j.exger.2003.09.010.

PMID: 14698810 Review.

195.

Diffuse form of argyrophilic grain disease: a new variant of four-repeat tauopathy different from limbic argyrophilic grain disease.

Maurage CA, Sergeant N, Schraen-Maschke S, Lebert F, Ruchoux MM, Sablonnière B, Pasquier F, Delacourte A.

Acta Neuropathol. 2003 Dec;106(6):575-83. doi: 10.1007/s00401-003-0762-6. Epub 2003 Sep 27.

PMID: 14517683

196.

Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains.

Ledesma MD, Abad-Rodriguez J, Galvan C, Biondi E, Navarro P, Delacourte A, Dingwall C, Dotti CG.

EMBO Rep. 2003 Dec;4(12):1190-6. doi: 10.1038/sj.embor.7400021. Epub 2003 Nov 14.

PMID: 14618158 Free PMC article.

197.

Stable-tau overexpression in human neuroblastoma cells: an open door for explaining neuronal death in tauopathies.

Delobel P, Mailliot C, Hamdane M, Sambo AV, Bégard S, Violleau A, Delacourte A, Buée L.

Ann N Y Acad Sci. 2003 Dec;1010:623-34. doi: 10.1196/annals.1299.115.

PMID: 15033802 Review.

198.

Microtubule-associated protein tau gene: a risk factor in human neurodegenerative diseases.

Schraen-Maschke S, Dhaenens CM, Delacourte A, Sablonnière B.

Neurobiol Dis. 2004 Apr;15(3):449-60. doi: 10.1016/j.nbd.2003.12.009.

PMID: 15056452 Review.

199.

Examination of stress-related genes in human temporal versus occipital cortex in the course of neurodegeneration: involvement of 14-3-3 zeta in this dynamic process.

Soulié C, Nicole A, Delacourte A, Ceballos-Picot I.

Neurosci Lett. 2004 Jul 15;365(1):1-5. doi: 10.1016/j.neulet.2004.03.090.

PMID: 15234461

200.

Protein levels of glycogen synthase 3 kinase are normal in progressive supranuclear palsy.

Borghi R, Piccini A, Delacourte A, Strocchi P, Zaccheo D, Tabaton M.

Neurosci Lett. 2004 Aug 5;366(1):67-70. doi: 10.1016/j.neulet.2004.05.014.

PMID: 15265592

201.

A non-DM1, non-DM2 multisystem myotonic disorder with frontotemporal dementia: phenotype and suggestive mapping of the DM3 locus to chromosome 15q21-24.

Le Ber I, Martinez M, Campion D, Laquerrière A, Bétard C, Bassez G, Girard C, Saugier-Veber P, Raux G, Sergeant N, Magnier P, Maisonobe T, Eymard B, Duyckaerts C, Delacourte A, Frebourg T, Hannequin D.

Brain. 2004 Sep;127(Pt 9):1979-92. doi: 10.1093/brain/awh216. Epub 2004 Jun 23.

PMID: 15215218

202.

Association study of three polymorphisms of kinesin light-chain 1 gene with Alzheimer's disease.

Dhaenens CM, Van Brussel E, Schraen-Maschke S, Pasquier F, Delacourte A, Sablonnière B.

Neurosci Lett. 2004 Sep 30;368(3):290-2. doi: 10.1016/j.neulet.2004.07.040.

PMID: 15364413

203.

Coexistence of reactive plasticity and neurodegeneration in Alzheimer diseased brains.

Guevara J, Dilhuydy H, Espinosa B, Delacourte A, Quirion R, Mena R, Joanette Y, Zenteno E, Robitaille Y.

Histol Histopathol. 2004 Oct;19(4):1075-84. doi: 10.14670/HH-19.1075.

PMID: 15375749

204.

Hypertension and progressive supranuclear palsy: is everything so clear?

Sibon I, Macia F, Vital A, Delacourte A, Tison F.

Mov Disord. 2004 Oct;19(10):1259-61. doi: 10.1002/mds.20275.

PMID: 15390036 No abstract available.

205.

Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model.

Casas C, Sergeant N, Itier JM, Blanchard V, Wirths O, van der Kolk N, Vingtdeux V, van de Steeg E, Ret G, Canton T, Drobecq H, Clark A, Bonici B, Delacourte A, Benavides J, Schmitz C, Tremp G, Bayer TA, Benoit P, Pradier L.

Am J Pathol. 2004 Oct;165(4):1289-300. doi: 10.1016/s0002-9440(10)63388-3.

PMID: 15466394 Free PMC article.

206.

Endothelin-converting enzyme-1 is expressed in human cerebral cortex and protects against Alzheimer's disease.

Funalot B, Ouimet T, Claperon A, Fallet C, Delacourte A, Epelbaum J, Subkowski T, Léonard N, Codron V, David JP, Amouyel P, Schwartz JC, Helbecque N.

Mol Psychiatry. 2004 Dec;9(12):1122-8, 1059. doi: 10.1038/sj.mp.4001584.

PMID: 15340356 Clinical Trial.

207.

Tau aggregates are abnormally phosphorylated in inclusion body myositis and have an immunoelectrophoretic profile distinct from other tauopathies.

Maurage CA, Bussière T, Sergeant N, Ghesteem A, Figarella-Branger D, Ruchoux MM, Pellissier JF, Delacourte A.

Neuropathol Appl Neurobiol. 2004 Dec;30(6):624-34. doi: 10.1111/j.1365-2990.2004.00577.x.

PMID: 15541003

208.

Neuronal membrane cholesterol loss enhances amyloid peptide generation.

Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, Dingwall C, De Strooper B, Dotti CG.

J Cell Biol. 2004 Dec 6;167(5):953-60. doi: 10.1083/jcb.200404149.

PMID: 15583033 Free PMC article.

209.

Tauopathies: recent insights into old diseases.

Delacourte A.

Folia Neuropathol. 2005;43(4):244-57.

PMID: 16416389 Review.

210.

Tau protein as a differential biomarker of tauopathies.

Sergeant N, Delacourte A, Buée L.

Biochim Biophys Acta. 2005 Jan 3;1739(2-3):179-97. doi: 10.1016/j.bbadis.2004.06.020.

PMID: 15615637 Review.

211.

Proteasome inhibition and Tau proteolysis: an unexpected regulation.

Delobel P, Leroy O, Hamdane M, Sambo AV, Delacourte A, Buée L.

FEBS Lett. 2005 Jan 3;579(1):1-5. doi: 10.1016/j.febslet.2004.11.018.

PMID: 15620682 Free PMC article.

212.

Effects of Abeta1-42 fibrils and of the tetrapeptide Pr-IIGL on the phosphorylation state of the tau-protein and on the alpha7 nicotinic acetylcholine receptor in vitro.

Lain E, Penke B, Delacourte A, Gündisch D, Schröder H, Witter B.

Eur J Neurosci. 2005 Feb;21(4):879-88. doi: 10.1111/j.1460-9568.2005.03909.x.

PMID: 15787694

213.

p25/Cdk5-mediated retinoblastoma phosphorylation is an early event in neuronal cell death.

Hamdane M, Bretteville A, Sambo AV, Schindowski K, Bégard S, Delacourte A, Bertrand P, Buée L.

J Cell Sci. 2005 Mar 15;118(Pt 6):1291-8. doi: 10.1242/jcs.01724. Epub 2005 Mar 1.

PMID: 15741232

214.

Expression of human FE65 in amyloid precursor protein transgenic mice is associated with a reduction in beta-amyloid load.

Santiard-Baron D, Langui D, Delehedde M, Delatour B, Schombert B, Touchet N, Tremp G, Paul MF, Blanchard V, Sergeant N, Delacourte A, Duyckaerts C, Pradier L, Mercken L.

J Neurochem. 2005 Apr;93(2):330-8. doi: 10.1111/j.1471-4159.2005.03026.x.

PMID: 15816856

215.

Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism.

Vingtdeux V, Hamdane M, Gompel M, Bégard S, Drobecq H, Ghestem A, Grosjean ME, Kostanjevecki V, Grognet P, Vanmechelen E, Buée L, Delacourte A, Sergeant N.

Neurobiol Dis. 2005 Nov;20(2):625-37. doi: 10.1016/j.nbd.2005.05.004. Epub 2005 Jun 3.

PMID: 15936948

216.

Similar brain tau pathology in DM2/PROMM and DM1/Steinert disease.

Maurage CA, Udd B, Ruchoux MM, Vermersch P, Kalimo H, Krahe R, Delacourte A, Sergeant N.

Neurology. 2005 Nov 22;65(10):1636-8. doi: 10.1212/01.wnl.0000184585.93864.4e.

PMID: 16301494

217.

[Animal models of Alzheimer's disease: a road full of pitfalls].

Delacourte A, Buée L.

Psychol Neuropsychiatr Vieil. 2005 Dec;3(4):261-70.

PMID: 16316817 Review. French.

218.

The natural and molecular history of Alzheimer's disease.

Delacourte A.

J Alzheimers Dis. 2006;9(3 Suppl):187-94. doi: 10.3233/jad-2006-9s322.

PMID: 16914858

219.

Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies.

Deramecourt V, Bombois S, Maurage CA, Ghestem A, Drobecq H, Vanmechelen E, Lebert F, Pasquier F, Delacourte A.

J Neuropathol Exp Neurol. 2006 Mar;65(3):278-88. doi: 10.1097/01.jnen.0000205145.54457.ea.

PMID: 16651889

220.

Pin1 allows for differential Tau dephosphorylation in neuronal cells.

Hamdane M, Dourlen P, Bretteville A, Sambo AV, Ferreira S, Ando K, Kerdraon O, Bégard S, Geay L, Lippens G, Sergeant N, Delacourte A, Maurage CA, Galas MC, Buée L.

Mol Cell Neurosci. 2006 May-Jun;32(1-2):155-60. doi: 10.1016/j.mcn.2006.03.006. Epub 2006 May 11.

PMID: 16697218

221.

Retinoic acid normalizes nuclear receptor mediated hypo-expression of proteins involved in beta-amyloid deposits in the cerebral cortex of vitamin A deprived rats.

Husson M, Enderlin V, Delacourte A, Ghenimi N, Alfos S, Pallet V, Higueret P.

Neurobiol Dis. 2006 Jul;23(1):1-10. doi: 10.1016/j.nbd.2006.01.008. Epub 2006 Mar 10.

PMID: 16531051

222.

ETR-3 represses Tau exons 2/3 inclusion, a splicing event abnormally enhanced in myotonic dystrophy type I.

Leroy O, Dhaenens CM, Schraen-Maschke S, Belarbi K, Delacourte A, Andreadis A, Sablonnière B, Buée L, Sergeant N, Caillet-Boudin ML.

J Neurosci Res. 2006 Sep;84(4):852-9. doi: 10.1002/jnr.20980.

PMID: 16862542

223.

[From physiopathology to treatment of Alzheimer's disease].

Delacourte A.

Rev Neurol (Paris). 2006 Oct;162(10):909-12. doi: 10.1016/s0035-3787(06)75099-8.

PMID: 17028557 Review. French.

224.

[Tauopathy and Alzheimer disease: a full degenerating process].

Buée L, Delacourte A.

Psychol Neuropsychiatr Vieil. 2006 Dec;4(4):261-73.

PMID: 17194646 Review. French.

225.

Sp3 and sp4 transcription factor levels are increased in brains of patients with Alzheimer's disease.

Boutillier S, Lannes B, Buée L, Delacourte A, Rouaux C, Mohr M, Bellocq JP, Sellal F, Larmet Y, Boutillier AL, Loeffler JP.

Neurodegener Dis. 2007;4(6):413-23. doi: 10.1159/000107701. Epub 2007 Oct 9.

PMID: 17934324

226.

Intracellular pH regulates amyloid precursor protein intracellular domain accumulation.

Vingtdeux V, Hamdane M, Bégard S, Loyens A, Delacourte A, Beauvillain JC, Buée L, Marambaud P, Sergeant N.

Neurobiol Dis. 2007 Mar;25(3):686-96. doi: 10.1016/j.nbd.2006.09.019. Epub 2007 Jan 3.

PMID: 17207630

227.

Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia.

Bombois S, Maurage CA, Gompel M, Deramecourt V, Mackowiak-Cordoliani MA, Black RS, Lavielle R, Delacourte A, Pasquier F.

Arch Neurol. 2007 Apr;64(4):583-7. doi: 10.1001/archneur.64.4.583.

PMID: 17420322

228.

Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity.

Ma H, Lesné S, Kotilinek L, Steidl-Nichols JV, Sherman M, Younkin L, Younkin S, Forster C, Sergeant N, Delacourte A, Vassar R, Citron M, Kofuji P, Boland LM, Ashe KH.

Proc Natl Acad Sci U S A. 2007 May 8;104(19):8167-72. doi: 10.1073/pnas.0609521104. Epub 2007 Apr 30.

PMID: 17470798 Free PMC article.

229.

BRCA1 may modulate neuronal cell cycle re-entry in Alzheimer disease.

Evans TA, Raina AK, Delacourte A, Aprelikova O, Lee HG, Zhu X, Perry G, Smith MA.

Int J Med Sci. 2007 May 12;4(3):140-5. doi: 10.7150/ijms.4.140.

PMID: 17505559 Free PMC article.

230.

Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies.

Vingtdeux V, Hamdane M, Loyens A, Gelé P, Drobeck H, Bégard S, Galas MC, Delacourte A, Beauvillain JC, Buée L, Sergeant N.

J Biol Chem. 2007 Jun 22;282(25):18197-18205. doi: 10.1074/jbc.M609475200. Epub 2007 Apr 27.

PMID: 17468104

231.

Ageing and amyloid-beta peptide deposition contribute to an impaired brain tissue plasminogen activator activity by different mechanisms.

Cacquevel M, Launay S, Castel H, Benchenane K, Chéenne S, Buée L, Moons L, Delacourte A, Carmeliet P, Vivien D.

Neurobiol Dis. 2007 Aug;27(2):164-73. doi: 10.1016/j.nbd.2007.04.004. Epub 2007 Apr 24.

PMID: 17566751

232.

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P.

Lancet Neurol. 2007 Aug;6(8):734-46. doi: 10.1016/S1474-4422(07)70178-3.

PMID: 17616482 Review.

233.

Tau, a biological marker of neurodegenerative diseases.

Delacourte A.

Handb Clin Neurol. 2008;89:161-72. doi: 10.1016/S0072-9752(07)01215-8.

PMID: 18631741 No abstract available.

234.

Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: two individual consequences of CUG trinucleotide repeats.

Dhaenens CM, Schraen-Maschke S, Tran H, Vingtdeux V, Ghanem D, Leroy O, Delplanque J, Vanbrussel E, Delacourte A, Vermersch P, Maurage CA, Gruffat H, Sergeant A, Mahadevan MS, Ishiura S, Buée L, Cooper TA, Caillet-Boudin ML, Charlet-Berguerand N, Sablonnière B, Sergeant N.

Exp Neurol. 2008 Apr;210(2):467-78. doi: 10.1016/j.expneurol.2007.11.020. Epub 2007 Dec 4.

PMID: 18177861

235.

Biochemistry of Tau in Alzheimer's disease and related neurological disorders.

Sergeant N, Bretteville A, Hamdane M, Caillet-Boudin ML, Grognet P, Bombois S, Blum D, Delacourte A, Pasquier F, Vanmechelen E, Schraen-Maschke S, Buée L.

Expert Rev Proteomics. 2008 Apr;5(2):207-24. doi: 10.1586/14789450.5.2.207.

PMID: 18466052 Review.

236.

Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.

Hébert SS, Horré K, Nicolaï L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, Kauppinen S, Delacourte A, De Strooper B.

Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6415-20. doi: 10.1073/pnas.0710263105. Epub 2008 Apr 23.

PMID: 18434550 Free PMC article.

237.Tau pathology and neurodegeneration: an obvious but misunderstood link.

Delacourte A.

J Alzheimers Dis. 2008 Aug;14(4):437-40. doi: 10.3233/jad-2008-14412.

PMID: 18688095 Review.

238.

Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease.

Kashani A, Lepicard E, Poirel O, Videau C, David JP, Fallet-Bianco C, Simon A, Delacourte A, Giros B, Epelbaum J, Betancur C, El Mestikawy S.

Neurobiol Aging. 2008 Nov;29(11):1619-30. doi: 10.1016/j.neurobiolaging.2007.04.010. Epub 2007 May 24.

PMID: 17531353

239.

The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons.

Thathiah A, Spittaels K, Hoffmann M, Staes M, Cohen A, Horré K, Vanbrabant M, Coun F, Baekelandt V, Delacourte A, Fischer DF, Pollet D, De Strooper B, Merchiers P.

Science. 2009 Feb 13;323(5916):946-51. doi: 10.1126/science.1160649.

PMID: 19213921

240.

MicroRNA regulation of Alzheimer's Amyloid precursor protein expression.

Hébert SS, Horré K, Nicolaï L, Bergmans B, Papadopoulou AS, Delacourte A, De Strooper B.

Neurobiol Dis. 2009 Mar;33(3):422-8. doi: 10.1016/j.nbd.2008.11.009. Epub 2008 Dec 9.

PMID: 19110058

241.

Neuroimaging outcomes in clinical trials in Alzheimer's disease.

Frisoni GB, Delacourte A.

J Nutr Health Aging. 2009 Mar;13(3):209-12. doi: 10.1007/s12603-009-0060-7.

PMID: 19262955 Review.

242.

Calpain hydrolysis of alpha- and beta2-adaptins decreases clathrin-dependent endocytosis and may promote neurodegeneration.

Rudinskiy N, Grishchuk Y, Vaslin A, Puyal J, Delacourte A, Hirling H, Clarke PG, Luthi-Carter R.

J Biol Chem. 2009 May 1;284(18):12447-58. doi: 10.1074/jbc.M804740200. Epub 2009 Feb 24.

PMID: 19240038 Free PMC article.

243.

Association of corticobasal degeneration and Huntington's disease: can Tau aggregates protect Huntingtin toxicity?

Caparros-Lefebvre D, Kerdraon O, Devos D, Dhaenens CM, Blum D, Maurage CA, Delacourte A, Sablonnière B.

Mov Disord. 2009 May 15;24(7):1089-90. doi: 10.1002/mds.22204.

PMID: 19243029 No abstract available.

244.

Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease.

Hudry E, Van Dam D, Kulik W, De Deyn PP, Stet FS, Ahouansou O, Benraiss A, Delacourte A, Bougnères P, Aubourg P, Cartier N.

Mol Ther. 2010 Jan;18(1):44-53. doi: 10.1038/mt.2009.175. Epub 2009 Aug 4.

PMID: 19654569 Free PMC article.

245.

Revising the definition of Alzheimer's disease: a new lexicon.

Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P.

Lancet Neurol. 2010 Nov;9(11):1118-27. doi: 10.1016/S1474-4422(10)70223-4. Epub 2010 Oct 9.

PMID: 20934914

246.

Multidisciplinary medical identification of a French king's head (Henri IV).

Charlier P, Huynh-Charlier I, Poupon J, Keyser C, Lancelot E, Favier D, Vignal JN, Sorel P, Chaillot PF, Boano R, Grilletto R, Delacourte S, Duriez JM, Loublier Y, Campos P, Willerslev E, Gilbert MT, Eisenberg L, Ludes B, de la Grandmaison GL.

BMJ. 2010 Dec 14;341:c6805. doi: 10.1136/bmj.c6805.

PMID: 21156748 No abstract available.

247.

Chloroquine and chloroquinoline derivatives as models for the design of modulators of amyloid Peptide precursor metabolism.

Melnyk P, Vingtdeux V, Burlet S, Eddarkaoui S, Grosjean ME, Larchanché PE, Hochart G, Sergheraert C, Estrella C, Barrier M, Poix V, Plancq P, Lannoo C, Hamdane M, Delacourte A, Verwaerde P, Buée L, Sergeant N.

ACS Chem Neurosci. 2015 Apr 15;6(4):559-69. doi: 10.1021/cn5003013. Epub 2015 Feb 6.

PMID: 25611616